ArticleCancer cell2018
Th9 Cells Represent a Unique Subset of CD4
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 109 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed.
- CD4Cell death & disease · 2022Trial
- Review
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A fungi-derived cyclic peptide enhances Th9-mediated antitumor immunity by targeting ZAP70 and SREBP1.The Journal of clinical investigation · 2026Article
- Emerging role of RNA modification reader YTHDF2 in hematopoiesis, immunity, and cancer.MedScience · 2026Review
- Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes.Journal for immunotherapy of cancer · 2026Article
- Immunosenescence: Shaping the Hematological Narrative in the Era of Aging.Aging and disease · 2025Review
- Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy.Nature immunology · 2025Article
- Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.Scientific reports · 2025Article
- Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8Cancer immunology, immunotherapy : CII · 2025Article
- Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Chimeric antigen receptor T cell therapy based on stem cell-like memory T cells enhances anti-tumour effects in multiple myeloma.Clinical and translational medicine · 2025Article
- Metabolic regulation of Th9 cell differentiation: insights for IL-9-driven diseases.Frontiers in immunology · 2025Review
- Differences in the peripheral blood immune landscape between early-onset and late-onset colorectal cancer.Frontiers in immunology · 2025Article
- Hypofractionated radiotherapy followed by rhGM-CSF enhances immunogenic cell death in a murine model of pancreatic cancer.Acta cirurgica brasileira · 2025Article
- CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells.Cell reports. Medicine · 2024Article
- Natural lung-tropic TJournal for immunotherapy of cancer · 2024Article
- Functional diversity and regulation of IL-9-producing T cells in cancer immunotherapy.Cancer letters · 2024Review
- Sphingosylphosphorylcholine Promotes Th9 Cell Differentiation Through Regulation of Smad3, STAT5, and β-Catenin Pathways.Immune network · 2024Article
- Fatty acid metabolism constrains Th9 cell differentiation and antitumor immunity via the modulation of retinoic acid receptor signaling.Cellular & molecular immunology · 2024Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byT2018
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
The antitumor effector T helper 1 (Th1) and Th17 cells represent two T cell paradigms: short-lived cytolytic Th1 cells and "stem cell-like" memory Th17 cells. We report that Th9 cells represent a third paradigm-they are less-exhausted, fully cytolytic, and hyperproliferative. Only tumor-specific Th9 cells completely eradicated advanced tumors, maintained a mature effector cell signature with cytolytic activity as strong as Th1 cells, and persisted as long as Th17 cells in vivo. Th9 cells displayed a unique Pu.1-Traf6-NF-κB activation-driven hyperproliferative feature, suggesting a persistence mechanism rather than an antiapoptotic strategy. Th9 antitumor efficacy depended on interleukin-9 and upregulated expression of Eomes and Traf6. Thus, tumor-specific Th9 cells are a more effective CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.